Scarica l'app Stockscreener
4.19
3.20%
0.13
Dopo l'orario di chiusura:
4.17
-0.02
-0.48%
Precedente Chiudi:
$4.06
Aprire:
$4.06
Volume 24 ore:
1.71M
Relative Volume:
0.50
Capitalizzazione di mercato:
$709.93M
Reddito:
$101.21M
Utile/perdita netta:
$-569.00K
Rapporto P/E:
-209.50
EPS:
-0.02
Flusso di cassa netto:
$-56.88M
1 W Prestazione:
+6.08%
1M Prestazione:
-0.95%
6M Prestazione:
+40.13%
1 anno Prestazione:
+274.11%
Intervallo 1D:
$3.9807
$4.21
Intervallo di 1 settimana:
$3.78
$4.21
Portata 52W:
$0.40
$4.62
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Nome
Cytomx Therapeutics Inc
Settore
Industria
Telefono
650.515.3185
Indirizzo
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Confronta CTMX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
4.19 | 687.91M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-09-17 | Ripresa | Barclays | Overweight |
| 2025-07-31 | Iniziato | Oppenheimer | Outperform |
| 2025-05-15 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Ripresa | Piper Sandler | Overweight |
| 2024-05-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-05-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-04-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2022-07-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-06-24 | Iniziato | BMO Capital Markets | Outperform |
| 2022-01-18 | Aggiornamento | Barclays | Underweight → Overweight |
| 2021-11-15 | Iniziato | BTIG Research | Buy |
| 2021-05-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Iniziato | JP Morgan | Overweight |
| 2021-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-09-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-06-01 | Downgrade | Jefferies | Buy → Hold |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-24 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-04 | Iniziato | Barclays | Equal Weight |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-11-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-13 | Iniziato | Mizuho | Buy |
| 2019-05-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Iniziato | Barclays | Overweight |
| 2018-11-26 | Iniziato | Piper Jaffray | Overweight |
| 2018-10-15 | Iniziato | Goldman | Neutral |
| 2018-09-13 | Iniziato | H.C. Wainwright | Buy |
| 2018-06-01 | Iniziato | SunTrust | Buy |
| 2018-01-05 | Iniziato | Citigroup | Buy |
| 2017-09-08 | Iniziato | Wedbush | Outperform |
| 2017-03-27 | Iniziato | H.C. Wainwright | Buy |
| 2017-03-02 | Iniziato | Instinet | Buy |
| 2017-01-03 | Downgrade | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Cytomx Therapeutics Inc Borsa (CTMX) Ultime notizie
Can CytomX Therapeutics Stock Recover If Markets Fall? - Trefis
What analysts say about CytomX Therapeutics Inc stockVolume Weighted Average Price & Explosive Profit Potential - earlytimes.in
With CytomX Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis
What Analysts Think Is Changing the CytomX Therapeutics Story After Recent Cancer Developments - Yahoo Finance
CytomX Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of key data By Investing.com - Investing.com South Africa
CytomX Therapeutics stock maintains Buy rating at H.C. Wainwright ahead of key data - Investing.com UK
Is CytomX Therapeutics Inc. stock a contrarian buyJuly 2025 PostEarnings & Technical Confirmation Alerts - Newser
Will CytomX Therapeutics Inc. stock beat EPS estimatesMarket Performance Report & Reliable Breakout Forecasts - Newser
Is CytomX Therapeutics Inc. (6C1) stock suitable for passive index funds2025 Earnings Surprises & Safe Entry Momentum Tips - Newser
Why CytomX Therapeutics Inc. (6C1) stock is listed among top recommendationsTrade Entry Report & High Accuracy Trade Alerts - Newser
Is CytomX Therapeutics Inc. (6C1) stock attractive post correctionProduct Launch & Real-Time Stock Movement Alerts - Newser
Published on: 2025-12-04 14:11:00 - Newser
Will CytomX Therapeutics Inc. (6C1) stock sustain dividend payoutsJuly 2025 Sector Moves & Verified Short-Term Plans - Newser
Would You Still Hold CytomX Therapeutics Stock If It Fell Another 30%? - Trefis
CytomX Therapeutics (NASDAQ:CTMX) Trading Down 6.5%What's Next? - MarketBeat
Is CytomX Therapeutics Inc. (6C1) stock ideal for retirement investorsJuly 2025 Patterns & Fast Gain Stock Trading Tips - Newser
What insider purchases suggest about CytomX Therapeutics Inc. (6C1) stockFed Meeting & Fast Gain Stock Trading Tips - Newser
Is CytomX Therapeutics Inc. (6C1) stock a buy on weaknessQuarterly Trade Summary & Fast Entry High Yield Tips - Newser
Will CytomX Therapeutics Inc. (6C1) stock outperform Dow JonesSell Signal & High Return Stock Watch Alerts - Newser
How CytomX Therapeutics Inc. (6C1) stock reacts to weak economy2025 Price Targets & Entry Point Confirmation Alerts - Newser
Portfolio Shifts: Is CytomX Therapeutics Inc 6C1 stock undervalued by metricsWeekly Loss Report & Daily Technical Stock Forecast Reports - BỘ NỘI VỤ
Will CytomX Therapeutics Inc. (6C1) stock benefit from infrastructure billWeekly Volume Report & High Conviction Buy Zone Picks - Newser
Why CytomX Therapeutics Inc. (6C1) stock is a strong buy callQuarterly Profit Report & Daily Market Momentum Tracking - Newser
What analyst consensus says on CytomX Therapeutics Inc. stockMarket Performance Summary & Risk Managed Trade Strategies - Newser
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
CapEx per share of CytomX Therapeutics, Inc. – DUS:6C1 - TradingView
Revenue per share of CytomX Therapeutics, Inc. – DUS:6C1 - TradingView
Operating cash flow per share of CytomX Therapeutics, Inc. – DUS:6C1 - TradingView
Is CytomX Therapeutics Inc. stock a top pick in earnings seasonJuly 2025 Decliners & Real-Time Volume Analysis Alerts - moha.gov.vn
Franklin Resources Inc. Invests $13.10 Million in CytomX Therapeutics, Inc. $CTMX - MarketBeat
CytomX Therapeutics jumps 54% after Q1 beat, prices $100M offering - MSN
CTMX (CytomX Therapeutics) Other Income (Minority Interest) : $0.0 Mil (TTM As of Sep. 2025) - GuruFocus
CX-2051 Momentum and An Expanding Oncology Pipeline Strengthen CytomX Therapeutics’ (CTMX) Investment Case - Insider Monkey
Will CytomX Therapeutics Inc. stock recover faster than peers2025 Historical Comparison & Fast Entry High Yield Tips - moha.gov.vn
Is CytomX Therapeutics Inc. (6C1) stock attractive for dividend growthJuly 2025 Snapshot & Technical Pattern Based Buy Signals - moha.gov.vn
Can CytomX Therapeutics Inc. stock sustain free cash flow growth2025 Price Targets & Weekly Watchlist for Hot Stocks - BỘ NỘI VỤ
Will CytomX Therapeutics Inc. stock split attract more investors2025 Key Lessons & Long-Term Growth Portfolio Plans - moha.gov.vn
ON Partners Recruits Chief Business Officer for CytomX Therapeutics - Hunt Scanlon Media
CytomX Therapeutics to Present at Upcoming December Investor Conferences - The Manila Times
CytomX Therapeutics (NASDAQ: CTMX) joins Evercore, Piper Sandler healthcare investor conferences in December - Stock Titan
Why Analysts Say the CytomX Story Is Evolving After Recent Clinical Momentum and Price Target Hike - Yahoo Finance
CytomX Therapeutics (CTMX) Price Target Increased by 15.12% to 7.21 - MSN
CytomX Therapeutics Inc Stock Analysis and ForecastVolume Profile Analysis & Superior Portfolio Investment - earlytimes.in
Will CytomX Therapeutics Inc. stock deliver consistent dividendsTrade Entry Report & Expert Curated Trade Setup Alerts - newser.com
Will CytomX Therapeutics Inc. stock see insider buyingEarnings Overview Summary & Low Risk High Reward Ideas - newser.com
Why CytomX Therapeutics Inc. (6C1) stock gets analyst attentionExit Point & High Accuracy Buy Signal Tips - newser.com
CTMX (CytomX Therapeutics) Price-to-Operating-Cash-Flow : (As of Nov. 20, 2025) - GuruFocus
CytomX at Jefferies Conference: Promising Cancer Treatment Insights By Investing.com - Investing.com Canada
CytomX Therapeutics stock holds Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Canada
Cytomx Therapeutics Inc Azioni (CTMX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.08%
0.91%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):